文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

慢性阻塞性肺疾病急性加重合并二氧化碳潴留患者全身糖皮质激素应用相关因素的临床研究

[Clinical investigation on the related factors for the application of systemic glucocorticoids in patients with acute exacerbation of chronic obstructive pulmonary disease with carbon dioxide retention].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论在AECOPD合并CO2潴留患者中,稳定期FEV1%高、入院EOS高、雾化吸入激素及无创通气可减少全身激素暴露,而频繁急性加重、心衰、PaCO2高则增加暴露。

该研究纳入2017年1月至2019年12月福建医科大学宁德市医院收治的AECOPD合并CO2潴留患者143例,按住院期间全身糖皮质激素累积泼尼松剂量≤200 mg(推荐剂量组,68例)或>200 mg(超量组,75例)分组,比较临床资料并行多因素Logistic回归。结果显示,稳定期FEV1%高(OR=0.957)、入院EOS高(OR=0.103)、雾化吸入激素(OR=0.337)及无创通气(OR=0.422)为减少全身激素暴露的保护因素;1年内急性加重频率高(OR=1.530)、心衰(OR=3.022)、PaCO2高(OR=1.062)为增加暴露的危险因素。提示上述因素可能有助于制定减少全身激素暴露的策略。

要点

  • 稳定期FEV1%越高,全身激素超量暴露风险越低(OR=0.957,95%CI 0.921-0.994,P=0.023)。
  • 入院EOS越高,全身激素超量暴露风险越低(OR=0.103,95%CI 0.016-0.684,P=0.019)。
  • 急性加重期使用雾化吸入激素(OR=0.337,95%CI 0.145-0.783)及无创通气(OR=0.422,95%CI 0.188-0.948)与减少全身激素暴露相关。
  • 1年内急性加重频率高(OR=1.530,95%CI 1.121-2.088)、合并心衰(OR=3.022,95%CI 1.263-7.231)、PaCO2高(OR=1.062,95%CI 1.010-1.115)增加全身激素暴露风险。
  • 该研究为单中心回顾性分析,上述相关因素需前瞻性验证,不能直接作为床旁决策阈值。

适用人群与场景

  • 2017年1月至2019年12月福建医科大学宁德市医院收治的AECOPD合并CO2潴留患者,共143例纳入分析(初始151例,排除8例)。

诊断标准与关键阈值

  • 按住院期间全身糖皮质激素累积泼尼松剂量分组:推荐剂量组为累积泼尼松剂量≤200 mg,超量组为累积泼尼松剂量>200 mg。

处置流程与药物剂量

  • 原文未提及具体的全身糖皮质激素给药方案、剂量调整或疗程推荐。
  • 原文未提及雾化吸入激素的具体药物、剂量或频次。
  • 原文未提及无创通气的具体参数设置或使用指征。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及相应处理。

研究设计与关键结果

  • 研究类型为单中心回顾性临床研究,纳入143例AECOPD合并CO2潴留患者,推荐剂量组68例,超量组75例。
  • 多因素Logistic回归显示,稳定期FEV1%高(OR=0.957,95%CI 0.921-0.994,P=0.023)、入院EOS高(OR=0.103,95%CI 0.016-0.684,P=0.019)、雾化吸入激素(OR=0.337,95%CI 0.145-0.783,P=0.011)、无创通气(OR=0.422,95%CI 0.188-0.948,P=0.037)为减少全身激素暴露的保护因素。
  • 1年内急性加重频率高(OR=1.530,95%CI 1.121-2.088,P=0.007)、合并心衰(OR=3.022,95%CI 1.263-7.231,P=0.013)、PaCO2高(OR=1.062,95%CI 1.010-1.115,P=0.018)为增加全身激素暴露的危险因素。
  • 单因素分析中,年龄、稳定期FEV1%、1年内急性加重频率、心衰比例、氧合指数、PaCO2、入院EOS、ApoE、雾化吸入激素比例及无创通气比例在两组间差异有统计学意义。

证据类型、等级与局限

  • 证据类型:单中心回顾性临床研究。
  • 原文未述局限性。

对床旁实践的改变

  • 对于AECOPD合并CO2潴留患者,稳定期FEV1%较高、入院EOS较高、使用雾化吸入激素或无创通气者,全身激素暴露水平可能较低;频繁急性加重、合并心衰或PaCO2较高者全身激素暴露可能较高,但上述均为相关性,不能直接作为减少或增加激素的决策依据。
  • 原文未提及该研究结果对具体临床实践改变的建议。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the factors affecting the application of systemic glucocorticoids in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with carbon dioxide (CO2) retention, and to guide the formulation of a strategy to reduce systemic glucocorticoid exposure.

METHODS: The AECOPD patients with CO2 retention admitted to the Ningde Municipal Hospital of Fujian Medical University from January 2017 to December 2019 were enrolled. The general information, past history, times of acute exacerbations within 1 year, pneumonia on admission, causes of COPD, heart failure, blood gas analysis, eosinophil count (EOS), albumin (Alb) and apolipoprotein E (ApoE) levels, exhaled nitric oxide (FeNO) level, inhaled glucocorticoid and non-invasive mechanical ventilation treatment at acute exacerbation were collected. The patients were divided into recommended dosage group (exposure levels in the recommended dosage range, cumulative prednisone dosage ≤ 200 mg) and exceeded group (exposure levels exceeded the recommended dose, cumulative prednisone dosage > 200 mg) according to cumulative systemic glucocorticoid exposure dosage of the patients during hospitalization. The clinical data of patients between the two groups were compared, and possible factors with P < 0.1 in univariate analysis were included in multivariate Logistic regression analysis to screen the related factors of systemic glucocorticoid exposure level in AECOPD patients with CO2 retention.

RESULTS: According to the order of hospitalization, 151 AECOPD patients with CO2 retention were enrolled, 8 patients were excluded, and 143 patients were enrolled in the analysis. Of the 143 patients, 68 received the recommended dose of systemic glucocorticoid, and 75 received excessive systemic glucocorticoid. Age, percentage of forced expiratory volume in 1 second (FEV1%) at stable phase, frequency of acute exacerbation within 1 year, heart failure ratio, oxygen index (PaO2/FiO2), arterial partial pressure of carbon dioxide (PaCO2), serum EOS and ApoE levels at admission, the ratio of aerosolized inhaled glucocorticoids and non-invasive mechanical ventilation showed statistical differences between the two groups. Multivariate Logistic regression analysis showed that related factors affecting systemic glucocorticoid exposure levels of AECOPD patients with CO2 retention were FEV1% at stable phase [odds ratio (OR) = 0.957, 95% confidence interval (95%CI) was 0.921-0.994, P = 0.023], acute exacerbation frequency within 1 year (OR = 1.530, 95%CI was 1.121-2.088, P = 0.007), heart failure (OR = 3.022, 95%CI was 1.263-7.231, P = 0.013), PaCO2 (OR = 1.062, 95%CI was 1.010-1.115, P = 0.018) and EOS at admission (OR = 0.103, 95%CI was 0.016-0.684, P = 0.019), aerosolized inhaled glucocorticoids (OR = 0.337, 95%CI was 0.145-0.783, P = 0.011) and non-invasive mechanical ventilation at acute exacerbation (OR = 0.422, 95%CI was 0.188-0.948, P = 0.037), of which high FEV1% at stable phase, high EOS at admission, aerosolized inhaled glucocorticoid and non-invasive mechanical ventilation at acute exacerbation were protective factors, while high frequency of acute exacerbation within 1 year, heart failure and high PaCO2 were risk factors.

CONCLUSIONS: For AECOPD patients with CO2 retention, high FEV1% at stable phase, high EOS level at admission, aerosolized inhaled glucocorticoid and non-invasive mechanical ventilation at acute exacerbation can reduce systemic glucocorticoid exposure. In addition, high frequency of acute exacerbation within 1 year, heart failure, and high PaCO2 can increase systemic glucocorticoid exposure.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Jiao W, Zhang W, Zhang C, et al. [Clinical investigation on the related factors for the application of systemic glucocorticoids in patients with acute exacerbation of chronic obstructive pulmonary disease with carbon dioxide retention]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33081891. doi:10.3760/cma.j.cn121430-20200302-00203

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。